Almirall, the pharmaceutical group, has reported to the Comisión Nacional del Mercado de Valores (CNMV), the agency in charge of supervising and inspecting the Spanish Stock Markets and the activities of all the participants in those markets, that it will dismiss up to 121 workers in Spain (10% of its entire workforce). The company explains that resources liberated through the restructuring measure will allow the company to continue supporting the new launching activities in the United States alongside the growth of the aesthetic section. Almirall has offices and manufacturing plants in Catalonia.
The trade union UGT expressed its rejection of the measure on the same day it was announced, pointing that it will ask the company management to reconsider the decision. While negotiation on the measure between the company and the trade union is taking place, Almirall has announced that between an increase in the profits equal to 41% from January to September in relation to the previous year.
Almirall has agreed with the trade unions to dismiss up to 102 workers (8.5% of its entire workforce). The agreement contemplates the possibility of voluntary leaves. In addition, an external outsourcing plan will be provided to to support the labour insertion of the workers affected. Almirall has increased its annual profits in September 2016 by 41%. Almirall has applied different employment adjustments in recent years. In 2014, it agreed with the trade unions the dismissals of 180 workers in Spain and 190 in its European subsidiary companies. In April 2015, it dismissed 59 workers from its R+D area